The incidence of obesity and diabetes, also known as the 'twin epidemics', is a rising global issue, particularly in developed nations. Therefore, cutting-edge therapeutic modalities are required. As the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, tirzepatide, also referred to as a 'twincretin', can significantly lower glycemic levels, improve insulin sensitivity, as well as reduce body weight by more than 20% and improve lipid metabolism. On the other hand, we have the USFDA and the EMA approved Semaglutide, a novel second-generation long-acting GLP-1RA for once-weekly subcutaneous administration, as an adjunct to diet and exercise in individuals with type 2 diabetes that is not well controlled. Join us LIVE as renowned endocrinologists Dr. Om Lakhani and Dr. Mayur Agrawal square off to discuss the benefits and drawbacks of each treatment.

Tirzepatide vs Semaglutide in Patients with Type 2 Diabetes

Medical Director & Consultant Endocrinologist, Hormone India Diabetes & Endocrine Centre, Bhopal

Managing diabetes isn’t one-size-fits-all - especially when it comes to vulnerable populations like pregnant women, the elderly, and hospitalized patients. Each group presents unique physiological challenges, risks, and therapeutic considerations that require careful adjustment of treatment goals and medications. In this session, **Dr. Mayur Agarwal** will discuss how to tailor diabetes management in these special situations, highlighting key clinical guidelines, safety concerns, and practical decision-making strategies. Tune in for an evidence-based, case-driven discussion that bridges gaps between theory and bedside care.

Dr. Mayur Agrawal

1

472

9k

4.5

Upcoming Sessions

Sessions Taken

799

4.4